What Happens When You Stop Ozempic or Wegovy? A Major New Study Has the Answer

If you're on Ozempic, Wegovy, Zepbound, or any GLP-1 medication, you've probably wondered: What happens if I stop? A major new study published in The BMJ has the most rigorous answer yet — and the findings have important implications for how patients and clinicians should think about long-term GLP-1 therapy.

The short version: most of the weight comes back, and faster than you might expect. But the full picture is more nuanced — and more important — than the headlines suggest.

What the Study Found

Researchers at Oxford University, led by Dr. Dimitrios Koutoukidis, conducted a comprehensive meta-analysis reviewing data from 9,341 patients across 37 studies testing 18 different weight-loss medications. Published in The BMJ in January 2026, it's one of the largest and most rigorous analyses of what happens after patients stop weight-loss drugs.

The headline numbers:

• Average weight regain: ~0.4 kg (just under 1 lb) per month after stopping any weight-loss medication
• Projected return to pre-treatment weight: ~1.7 years after stopping
• Cardiovascular benefits also reverse: Blood pressure and cholesterol levels that improved on the drugs were projected to return to pre-treatment levels within approximately 1.4 years

Roughly half of the study patients had taken GLP-1 medications. Among those who had taken semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) — the newer, more effective drugs — the monthly regain rate was notably faster: ~0.8 kg (1.8 lbs) per month.

The Counterintuitive Finding: Why Faster Regain Isn't Necessarily Worse

At first glance, the faster regain rate with semaglutide and tirzepatide sounds alarming. But context matters enormously here.

Because GLP-1 drugs produce significantly greater initial weight loss — often 15-20%+ of body weight compared to 5-10% with older medications — patients who stop have more weight to regain. Despite the faster monthly pace, the total time to return to pre-treatment baseline is actually similar to other medications: approximately 1.5 years for GLP-1 users vs. 1.7 years for all drugs combined.

"Because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time," said Dr. Koutoukidis. The mechanics are different — you lose more, you regain faster — but the destination is the same if you stop.

This finding challenges a common patient assumption: that GLP-1 drugs somehow "fix" obesity in a durable way that persists after discontinuation. The evidence strongly suggests they don't — at least not on average.

GLP-1 Drugs vs. Behavioral Programs: A Crucial Difference

The study also compared weight regain rates after stopping medications versus after completing behavioral weight management programs (diet, exercise, lifestyle interventions). The difference was striking: weight regain after drug discontinuation was approximately four times faster than after behavioral programs.

This doesn't mean medications are inferior — patients on GLP-1 drugs lose far more weight during treatment than they do through behavioral programs alone. But it does suggest that the weight-loss maintained after stopping is different in character. Behavioral programs may leave patients with habits and physiological adaptations that slow regain; drug-based losses may depend more heavily on the drug's ongoing presence to sustain suppression of appetite and metabolic rate.

What This Means for GLP-1 Therapy: A Chronic Disease Model

The findings reinforce what obesity medicine specialists have been saying for years, but what patients often struggle to accept: obesity is a chronic, relapsing disease that requires long-term treatment, not a one-time intervention.

"This isn't a failing of the medicines — it reflects the nature of obesity as a chronic, relapsing condition," said Dr. Sam West, lead author of related Oxford research. The same logic applies to other chronic conditions: if you stop taking blood pressure medication, your blood pressure returns. If you stop statins, your cholesterol returns. GLP-1 medications work the same way.

The clinical implications are significant:

• GLP-1 therapy should be framed as potentially long-term when patients start — not as a short-course intervention
• Discontinuation planning matters — if a patient needs to stop due to cost, side effects, or other reasons, they should have a plan for managing the expected rebound
• Affordability is a medical issue — if cost is what drives discontinuation, addressing the cost barrier is directly addressing a medical risk

The Cardiovascular Risk Dimension

Perhaps the most underreported finding in this study is the reversal of cardiovascular benefits. Patients who had improved blood pressure and cholesterol on GLP-1 drugs saw those improvements disappear within about 1.4 years of stopping — actually faster than the weight returned.

For patients who started GLP-1 therapy specifically for cardiovascular risk reduction (particularly semaglutide, which has FDA approval for reducing major adverse cardiovascular events), this finding is clinically important. Stopping the medication doesn't just mean regaining weight — it means losing the protective cardiovascular effect that some patients were prescribed it for in the first place.

This aligns with data from the SELECT trial, which showed Wegovy reducing cardiovascular events even in patients who weren't primarily focused on weight loss. Discontinuing treatment reverses that benefit on a similar timeline.

Who Is Most Likely to Keep Weight Off After Stopping?

This is the question patients most want answered — and the honest answer, per the study authors, is that we don't know yet. "Understanding who does well and who does not is a bit of a 'holy grail' question in weight-loss research, but nobody has the answer to that yet," said Dr. Koutoukidis.

The retrospective study design couldn't identify patient characteristics that predicted more durable weight loss after stopping. What we can say is that the average patient returns to baseline, but averages can obscure significant individual variation. Some patients do maintain meaningful weight loss after stopping; others regain rapidly.

Emerging research is beginning to identify potential predictors — including the degree of behavioral changes made during treatment, baseline metabolic health, and duration of treatment before stopping — but none of these are definitive yet.

What Should Patients on GLP-1 Drugs Do With This Information?

Don't panic, but do plan. Here's a practical framework:

If you're currently on a GLP-1 and it's working: This study is actually an argument for staying on your medication, particularly if weight management is important for your health. The evidence suggests that discontinuing successful treatment will, on average, reverse your gains within 1.5-2 years. If you're meeting your goals, continuing therapy preserves them.

If you're considering stopping due to cost: This is exactly the situation where exploring alternative pricing matters. The $50/month Medicare Zepbound deal, TrumpRx pricing (~$350/month for injectable semaglutide), and GoodRx's oral semaglutide at $149/month are all pathways that may make continued treatment financially viable. Stopping because you think you've "completed" treatment may not achieve the durable outcome you're hoping for.

If you do need to stop: Work with your provider on a transition plan. This might include intensive behavioral support, dietary adjustments, and a monitoring schedule for weight and cardiovascular metrics. Stopping abruptly without a plan is the worst-case scenario. Some evidence suggests a gradual taper may slow the rebound compared to abrupt discontinuation, though this hasn't been definitively proven in large trials.

If you're considering starting: Going in with realistic expectations is important. GLP-1 medications can produce remarkable results — but the evidence suggests they work best as long-term therapies. Patients who expect to take a drug for a year and then maintain results indefinitely may be setting themselves up for disappointment. Those who approach it as ongoing management of a chronic condition are more likely to have realistic expectations and stay on therapy long enough to benefit.

The Bigger Picture: Access and Affordability Now Matter More

If GLP-1 drugs need to be taken long-term to maintain their benefits, then the affordability of long-term access becomes a central medical question — not just a financial one. The $1,000/month era for these medications created a system where only the wealthiest or best-insured patients could sustain treatment.

The pricing changes of early 2026 — Medicare's $50/month Zepbound deal, TrumpRx, GoodRx for Weight Loss — are therefore more medically significant than they might appear. They're not just making GLP-1 drugs cheaper for a few months. They're potentially making long-term, evidence-based obesity treatment accessible for the first time to patients who couldn't afford indefinite continuation.

Will I gain all my weight back if I stop Ozempic?

On average, yes — the BMJ study found patients returned to pre-treatment weight within about 1.5-1.7 years of stopping any weight-loss medication, including GLP-1 drugs. Individual results vary, and some patients maintain more of their weight loss than others, but the average strongly suggests most weight returns without ongoing treatment.

Is stopping GLP-1 drugs dangerous?

Not in an acute sense — stopping GLP-1 medications does not cause dangerous withdrawal effects. However, the gradual reversal of weight loss and cardiovascular benefits over 1-2 years does represent a meaningful health risk for patients who stopped specifically because of those benefits. Talk to your provider before discontinuing.

Can you take GLP-1 drugs forever?

Long-term safety data continues to accumulate and looks reassuring so far, but most approved GLP-1 medications have been in widespread use for less than a decade. Clinicians increasingly treat GLP-1 therapy as a long-term intervention for chronic obesity — similar to statins for cholesterol or antihypertensives for blood pressure — but monitoring and periodic reassessment are appropriate.